Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

OncoCyte Corp (OCX) advances with new product launches and strategic alliances, while navigating regulatory hurdles and competitive pressures.

Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is ...

Q4 2024 Management View CEO Josh Riggs highlighted significant progress in advancing OncoCyte's clinical assay, including the launch of GraftAssure, a research-use-only kidney transplant test. The ...

OncoCyte (NASDAQ:OCX – Get Free Report)‘s stock had its “equal weight” rating reiterated by research analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $4.00 ...

Needham & Company LLC reiterated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $4.25 target price on ...

Oncocyte Corp. reports Q4 2024 revenue of $1.5 million, launching a new transplant assay and securing strategic partnerships. Oncocyte Corp. reported a revenue of $1.5 million for Q4 2024 and a ...

Oncocyte is at a pivotal stage in commercializing what we expect to be an industry-transforming organ transplant rejection monitoring test. We aim to deliver proven, more affordable, faster tests ...

OncoCyte plans to expand its clinical trial to include approximately six U.S. centers and additional European sites, enrolling 150 matched samples to demonstrate assay efficacy. Future updates ...

Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, ...

March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter ...